PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7]: A61K 33/24, 38/00 — A1

(11) International Publication Number: **WO 00/64455**

(43) International Publication Date: 2 November 2000 (02.11.00)

(21) International Application Number: PCT/US00/11000

(22) International Filing Date: 24 April 2000 (24.04.00)

(30) Priority Data:
09/300,124 27 April 1999 (27.04.99) US

(71) Applicant *(for all designated States except US)*: HEALTH RESEARCH, INC. [–/US]; Roswell Park Cancer Institute Division, Elm and Carlton Streets, Buffalo, NY 14263 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: PIVER, Steven, M. [–/US]; 315 Lincoln Parkway, Buffalo, NY 14216 (US). SILVER, David, F. [–/US]; 487 Delaware Avenue, Buffalo, NY 14202 (US).

(74) Agents: KADLE, Ranjana et al.; Hodgson, Russ, Andrews, Woods & Goodyear, LLP, Suite 2000, One M & T Plaza, Buffalo, NY 14203–2391 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD OF ENHANCING THE EFFICACY OF ANTI–TUMOR AGENTS



(57) Abstract

A method for enhancing the effect of anti–tumor agents on solid tumors is provided. The method comprises administering to an individual an anti–tumor agent and a hematocrit elevator. The hematocrit elevator may be administered before or concurrently with the anti–tumor agent.